NCT02125422

CompletedPhase 1

Neurophysiological Study of tDCS Effects in Healthy Voluntee...

University of Liege Source

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

CB-1200

Study Type

interventional

Actual enrollment (reported)

18

Locations

1 country

Sites

1

Timeline

Study Start

November 2013

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2013

Actual (reported)

Study Completion

April 2014

Actual (reported)

Brief Summary

Transcranial direct current stimulation is a tool to modulate cortical excitability.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 18 participants
Study completion date: April 2014
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
November 2013
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
December 2013
Actual (reported)
Study Completion
April 2014
Actual (reported)
First Submitted
April 18, 2014
Actual (reported)
First Posted
April 29, 2014
Actual (reported)

Last Updated: May 28, 2015
Status Verified: May 2015
Last Update Submitted: May 27, 2015

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (1)

Neurophysiological mesures changes
Modifications in neurophysiological test after direct current stimulation
up to 1 month

Other Outcomes (4)

VEP changes
up to 1 month
Blink changes
up to 1 month
CHEPS changes
up to 1 month
+1 more other outcomes

Study Arms (1)

Cefaly tDCS

EXPERIMENTAL

Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, for 5 consecutive days in 9 HV. The anode is placed over the left DLPFC. 2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, for 5 consecutive days in 9 HV

Device: Cefaly tDCS

Interventions

Cefaly tDCSDevice

Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.

Cefaly tDCS

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

healthy volunteers

You may not qualify if:

Sponsors & Collaborators

University of Liege
Otherlead

Study Sites (1)

Roberta Baschi

Liége, Liége, 4000, Belgium

Study Officials

Delphine Magis, MD
University of Liege
PRINCIPAL INVESTIGATOR
Jean Schoenen, MD
University of Liege
PRINCIPAL INVESTIGATOR

Enrollment

18 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NA
Masking: NONE
Purpose: BASIC SCIENCE
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Honorary Full Professor

Study Record Dates

First Submitted

April 18, 2014

First Posted

April 29, 2014

Study Start

November 2013

Date type not reported

This date has not been verified as actual or estimated.

Phase 1Completed

NCT02189330

A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples

Phase 1Completed

NCT01859377

Evaluation and Comparison of Systemic Exposure to Ibuprofen After Single Oromucosal Versus Oral Administrations

Phase 1Completed

NCT02316756

A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects

Phase 1Completed

NCT02217813

A Bioequivalence Study Comparing Two Different Tafamidis Formulations

Phase 1Completed

NCT02472912

Adalimumab PK Bioequivalence Study to EU and US Sourced Humira

Phase 1Completed

NCT01674322

A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Phase 1Completed

age below 18 or above 65 years

personal history of recurrent headache or other neurological diseases especially seizures,

familial history of recurrent headache

child migraine equivalents (motion sickness, cyclic vomiting or recurrent abdominal pain, somnambulism etc.. . .)

chronic pain syndromes

analgesics intake at the time of recording

contra-indications to tDCS neurostimulation (metal prosthetics in the head or internal stimulation like a pacemaker).

Contact the study team to confirm eligibility.

Primary Completion

December 2013

Actual (reported)

Study Completion

April 2014

Actual (reported)

Last Updated

May 28, 2015

Record last verified: 2015-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02125422
Data provider: ClinicalTrials.gov
Source updated: 2015-05-28
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:22:19 UTC

Locations

BE(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Other Outcomes (4)

Study Arms (1)

Cefaly tDCS

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations